|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Texas Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing TexasLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Oncolix Inc.
| | | Phone: | (281) 402-3167 | Fax: | (281) 698-2070 | Year Established: | 2006 | Ticker: | AEPP | Exchange: | OTC PINK | Main Contact: | Michael T. Redman, CEO & Chairman | | Company Description | Oncolix is a clinical-stage biotechnology company developing Prolanta for the treatment of ovarian, uterine, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta in its first indication, the treatment of ovarian cancer. This Phase 1 clinical trial began in 2016. Prolanta is a prolactin receptor antagonist (or blocker) that has demonstrated efficacy in xenograft models through a unique mechanism of action, autophagy. In addition to ovarian cancer, there is strong preclinical evidence Prolanta may be effective in breast, prostate and other cancers. | |
|
|
|
|
|